Delivery of GLP-1 receptor agonists by soft mist inhalation

The soft mist inhalation of GLP-1 receptor agonists addresses the drawbacks of injectable formulations by offering a convenient, stable, and effective pulmonary delivery system with reduced side effects and increased adherence.

WO2026233864A1PCT designated stage Publication Date: 2026-11-12INVOX BELGIUM NV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/062613
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-05
Filing Date
2026-04-30
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current GLP-1 receptor agonist formulations, such as semaglutide, are primarily administered via injections or pills, leading to increased costs, environmental waste, patient discomfort, and reduced adherence due to side effects like injection site reactions and pain, necessitating a more convenient and effective delivery method.

Method used

The administration of GLP-1 receptor agonists, like semaglutide, through a soft mist inhalation system that generates fine droplets for pulmonary delivery, maintaining dose purity and stability, and allowing for reproducible spraying characteristics.

Benefits of technology

The soft mist inhalation method provides a convenient, patient-friendly delivery with reduced side effects, enhanced bioavailability, and the ability to administer doses throughout the day, minimizing environmental impact and improving treatment adherence.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026062613_12112026_PF_FP_ABST
    Figure EP2026062613_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides an inhalable pharmaceutical composition comprising a GLP-1 receptor agonist, for use in the therapy of a subject; said therapy comprising administering the composition to the subject via a soft mist inhaler.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] DELIVERY OF GLP-1 RECEPTOR AGONISTS BY SOFT MIST INHALATION

[0002] TECHNICAL FIELD

[0003] The present invention concerns inhalable pharmaceutical compositions.

[0004] BACKGROUND

[0005] Glucagon-like peptide 1 (GLP-1) receptor agonists are a class of medications approved for the treatment of type II diabetes and obesity. They mimic the actions of the natural incretin hormone GLP-1, which is released by the gut after eating. By activating GLP-1 receptors, these drugs help lower blood sugar, reduce appetite, and may lead to weight loss.

[0006] In 2022, GLP-1 drug sales hit $22 billion worldwide. Currently, there are six approved GLP-1 receptor agonists available on the market: dulaglutide (TRULICITY), exenatide (BYETTA), liraglutide (VICTOZA and SAXENDA), lixisenatide (ADLYXIN), semaglutide (OZEMPIC, RYBELSUS, and WEGOVY), and tirzepatide (MOUNJARO).

[0007] Semaglutide, for example, is an anti-diabetic medication used for the treatment of type II diabetes and an anti-obesity medication used for long-term weight management. Semaglutide is a peptide similar to GLP-1 with a modified side chain. Specifically, it is a long-acting analogue of human glucagon like-1 peptide i.e. an Aib, Arg-GLP-l(7-37) analogue substituted on the s-amino group of the lysine residue in position 26 with an (S)-22,40-dicarboxy-10,19,24-trioxo-3,6,12,15-tetraoxa-9,18,23-triazatetracontan-l-oyl side chain. The side chain consists of two 8-amino-3, 6-dioxaoctanoic acid (ADO) spacers, one y-glutamic acid (Glu) spacer, and a fatty diacid (1, 18- octadecanedioic acid).

[0008] Currently, semaglutide is approved in an oral as well as injectable dosage form, and there are two approved injectable brands available, OZEMPIC and WEGOVY. OZEMPIC is currently approved for treatment of obesity and diabetes and is available in disposable pen injector and uses different devices for different doses. WEGOVY is presented as a clear and colourless solution for subcutaneous injection in a 1 mL prefilled type I glass syringe (PFS) attached with stainless steel needle, which is assembled into a single-use prefilled pen (PFP).

[0009] One of the major drawbacks of the currently approved GLP-1 receptor agonist formulations is that the dosage form is typically administered as injections and available either in disposable single pen injectors or fixed dose, multiple dose injectors. Oral tablet forms are also available.With injectable forms, a patient needs to use / buy a disposable pen every week or needs to buy a different pen injector for different doses as per the approved dosage regimen, and for the entire time period of the therapy. The pen provided for injecting is a single use pen and should be thrown out after each dose is administered. This not only increases the cost of therapy to the patient, but also unnecessary waste is generated, which also has an impact on the environment. Furthermore, the need for injections may lead to non-adherence by the patient (potentially due to undesirable side effects e.g. injection site reactions, bruising, and / or pain), and thus reduced treatment efficacy.

[0010] Accordingly, there is a need for new means of administering GLP-1 receptor agonists, which overcome the aforementioned drawbacks.

[0011] SUMMARY OF THE INVENTION

[0012] The present inventors have found soft mist inhalation administration of GLP-1 receptor agonists, e.g. semaglutide, to be a viable means of delivery. As detailed in the Examples, such administration results in an advantageous distribution of fine droplets, with over 50% of droplets (by volume) having a diameter of less than 5 pm, and over 90% of droplets (by volume) having a diameter of less than 10 pm -see e.g. Example 1. Accordingly, a substantial portion of the aerosolised composition generated by the soft mist inhaler will have the ability to penetrate the lungs and enter pulmonary circulation. Furthermore, surprisingly, the dose purity of e.g. semaglutide is maintained, with no evidence of degradation following administration - see e.g. Example 2. Furthermore, exemplary formulations of e.g. semaglutide exhibit good stability and advantageous, reproducible spraying characteristics following storage at 2-8°C or 25°C over periods of at least three months, and even at high peptide concentrations (see, e.g. Example 3).

[0013] The present invention is surprisingly effective - the potential for peptide instability at air-liquid interfaces, shear sensitivity during aerosolisation, and molecular weight limitations of SMI delivery may indicate a lack of efficacy, or at least limitations, of the delivery approach of the invention. However, as taught in the eamples, the inventors have surprisingly found inter alia, monomer content to be preserved, peptide stability to be maintained under impingement nozzle shear, a consistent droplet size to be achieved across device life, and reproducible performance to be achieved even at high peptide concentrations (e.g. 45 mg / mL of semaglutide, as in Example 3).According to a first aspect of the invention there is provided an inhalable pharmaceutical composition comprising a GLP-1 receptor agonist, for use in the therapy of a subject; said therapy comprising administering the composition to the subject via a soft mist inhaler.

[0014] According to a second aspect of the invention there is provided an aerosolised liquid pharmaceutical composition comprising a GLP-1 receptor agonist.

[0015] According to a third aspect of the invention there is provided an inhalation device for generating an aerosol, comprising: a housing having a user-facing side; at least one impingement-type nozzle for generating the aerosol by collision of at least two liquid jets, the nozzle being firmly affixed to the user-facing side of the housing such as to be immobile relative to the housing; a fluid reservoir arranged within the housing; and a pumping unit arranged within the housing, wherein the fluid reservoir is adapted to hold an inhalable pharmaceutical composition from which the aerosol is generated by the inhalation device; wherein the fluid reservoir comprises an inhalable pharmaceutical composition comprising a GLP-1 receptor agonist.

[0016] According to a fourth aspect of the invention there is provided a kit comprising: an inhalation device (e.g. a soft mist inhaler), and a pharmaceutical composition comprising a GLP-1 receptor agonist, wherein the pharmaceutical composition is contained within a cartridge.

[0017] According to a fifth aspect of the invention, there is provided a method of treating or preventing a disorder in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a GLP-1 receptor agonist, wherein said administering is performed via inhalation using a soft mist inhaler.

[0018] According to an additional aspect of the invention there is provided an inhalable pharmaceutical composition comprising a peptide therapeutic, for use in the therapy of a subject; said therapy comprising administering the composition to the subject via a soft mist inhaler.

[0019] According to an additional aspect of the invention there is provided an aerosolised liquid pharmaceutical composition comprising a peptide therapeutic.

[0020] According to an additional aspect of the invention there is provided an inhalation device for generating an aerosol, comprising: a housing having a user-facing side; at least one impingement-type nozzle for generating the aerosol by collision of at least two liquid jets, thenozzle being firmly affixed to the user-facing side of the housing such as to be immobile relative to the housing; a fluid reservoir arranged within the housing; and a pumping unit arranged within the housing, wherein the fluid reservoir is adapted to hold an inhalable pharmaceutical composition from which the aerosol is generated by the inhalation device; wherein the fluid reservoir comprises an inhalable pharmaceutical composition comprising a peptide therapeutic.

[0021] According to an additional aspect of the invention there is provided a kit comprising: an inhalation device (e.g. a soft mist inhaler), and a pharmaceutical composition comprising a peptide therapeutic, wherein the pharmaceutical composition is contained within a cartridge.

[0022] According to an additional aspect of the invention, there is provided a method of treating or preventing a disorder in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a peptide therapeutic, wherein said administering is performed via inhalation using a soft mist inhaler.

[0023] According to an additional aspect of the invention, there is provided an inhalable pharmaceutical composition comprising or consisting of a GLP-1 receptor agonist, a buffering agent, a salt, a surfactant and a preservative.

[0024] BRIEF DESCRIPTION OF THE FIGURES

[0025] The invention will now be more particularly described, by way of example only, with reference to the following figures, in which;

[0026] Figure 1 illustrates an inhalation device according to an embodiment of the invention, prior to use.

[0027] Figure 2 illustrates an alternative inhalation device according to the invention, without an outlet valve.

[0028] Figure 3 illustrates the inhalation device shown in Figure 1, with a filled pumping chamber.

[0029] Figure 4 illustrates the inhalation device shown in Figure 1, after the first actuation.

[0030] Figure 5 illustrates the inhalation device shown in Figure 1, at the end of the aerosol emission phase.

[0031] Figure 6 illustrates the inhalation device shown in Figure 1 , after the pumping chamber has been re-filled.Figure 7 shows the droplet size distribution achieved by the inhalation device as tested in Example 1.

[0032] Figure 8 shows the droplet size distribution achieved by the soft mist inhaler after semaglutide formulations were stored for 1 and 3 months at either 2-8°C or 25°C as tested in Example 3e.

[0033] DETAILED DESCRIPTION OF THE INVENTION

[0034] GLP-1 receptor agonists / peptide therapeutics

[0035] According to the invention, the pharmaceutical composition comprises a GLP-1 receptor agonist. GLP-1 receptor agonists, e.g. semaglutide, mimic the action of the natural hormone GLP-1, which helps regulate blood sugar and appetite. They stimulate insulin release when blood sugar is high and suppress glucagon secretion, leading to improved glycaemic control and potential weight loss.

[0036] According to additional aspects of the invention, the pharmaceutical composition comprises a peptide therapeutic, which, in some embodiments, is a GLP-1 receptor agonist. The invention may obviate adverse events associated with systemic exposure of peptide therapeutics, while also providing reproducible delivery performance at high peptide concentrations (see, e.g. Example 3, where 45 mg / ml of semaglutide was tested).

[0037] GLP-1 receptor agonists, e.g. semaglutide, are typically administered via injection or by ingesting pills, often requiring daily oral doses or weekly subcutaneous injections. This can lead to non-adherence and reduced treatment efficacy. However, according to the invention, inhaled delivery allows for a convenient administration method that minimises patient discomfort and avoids the need for frequent pill taking or injections (thereby minimising potential side effects associated with injections, e.g. injection site reactions, bruising, and / or pain). Advantageously, inhaled delivery presents a preferable alternative for patients, as it is easier to administer a medication, and provides alternatives for patients who have difficulties in swallowing pills, especially when the pills are large.

[0038] Furthermore, according to the invention, the rapid absorption of the GLP-1 receptor agonist via the lungs may offer enhanced bioavailability compared to the oral and subcutaneous routes, which may result in a quicker onset of action. Additionally, inhaled delivery minimises side effects associated with both subcutaneous and oral administration (not merely bruising and undesirable side effects associated with a needle, but also potential gastrointestinaleffects such as nausea and sickness). Additionally, inhaled delivery also provides a means for repeated dosing throughout the day, or once daily (but titrated or fractional) dosing if needed. In contrast, GLP-1 receptor agonist (e.g. semaglutide)-containing pills are typically approved for once-daily administration (e.g. a single fixed dose). Inhaled delivery enables a subject to take further amounts safely, throughout the day if needed; or to dose on a single occasion per day, but using titrated or fractional dosing (as opposed to repeated, ad-hoc administration) .

[0039] The GLP-1 receptor agonist may be a polypeptide, peptide or small molecule, and is preferably a polypeptide or peptide. The GLP-1 receptor agonist may be a GLP-1 peptide. The GLP-1 receptor agonist may be selected from semaglutide, liraglutide, exenatide, lixisenatide, dulaglutide, albiglutide, beinaglutide, PEG-loxenatide, tirzepatide, ASC30 and multi-agonist incretin peptides (e.g. dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonists, and triple GLP-1, GIP and glucagon agonists, e.g. retatrutide). Structural and functional analogues of semaglutide are also within the scope of the invention. Preferably, the GLP-1 receptor agonist is selected from semaglutide and liraglutide. More preferably, the GLP-1 receptor agonist is semaglutide.

[0040] Semaglutide may be prepared as described in Example 4 of W02006 / 097537. Semaglutide (CAS No. 910463-68-2) has the following structure:

[0041]

[0042] Therapeutic use

[0043] According the invention, the pharmaceutical composition is for use in the therapy of a subject. As used herein, “therapy” encompasses both treatment and prevention.

[0044] Generally, the pharmaceutical composition is for use in the therapy of a disorder in a subject, wherein the disorder is selected from a metabolic disorder, a cardiovascular disorder, a neurodegenerative disorder, kidney disease and cancer. Where the therapy is of a cardiovascular disorder, neurodegenerative disorder, kidney disease or cancer, these aregenerally obesity-associated. Furthermore, the therapy is generally preventative. For example, obesity-associated cancers include gallbladder cancer, meningioma, pancreatic cancer, hepatocellular carcinoma, ovarian cancer, colorectal cancer, multiple myeloma, esophageal cancer endometrial cancer and kidney cancer (with GLP-1 receptors agonists being associated with lower risk of such cancers, see e.g. Wang et al. JAMA Netw Open. 2024;7(7):e2421305).

[0045] Preferably, the pharmaceutical composition is for use in the therapy of a metabolic disorder in a subject. The metabolic disorder may be selected from obesity, diabetes (type II or type I diabetes, preferably type II diabetes), hyperglycaemia, impaired glucose tolerance, fatty liver disease (non-alcoholic or alcoholic fatty liver disease, preferably non-alcoholic fatty liver disease), cardiovascular disease and polycystic ovary syndrome. Preferably, the metabolic disorder is selected from obesity, type II diabetes, hyperglycaemia and impaired glucose tolerance. More preferably, the metabolic disorder is selected from obesity and type II diabetes.

[0046] According to the invention, the pharmaceutical composition may be for use in a method of reducing glycated haemoglobin (HbA1c) level in a subject. The pharmaceutical composition may be for use in a method of reducing HbA1c level in the therapy of a metabolic disorder in a subject. The pharmaceutical composition may be for use in a method of reducing HbA1c level in the therapy of obesity, type II diabetes, hyperglycaemia or impaired glucose tolerance in a subject.

[0047] According to the invention, the pharmaceutical composition may be for use in a method of reducing the body weight of a subject. The pharmaceutical composition may be for use in a method of reducing body weight in the therapy of obesity in a subject. The pharmaceutical composition may be for use in a method of reducing food intake in the therapy of obesity in a subject. The pharmaceutical composition may be for use in a method of inducing satiety in the therapy of obesity in a subject.

[0048] The subject may have an HbA1c level, e.g. prior to therapy, of 6.0% or greater, e.g. 6.1% or greater, 6.2% or greater, 6.3% or greater or 6.4% or greater; preferably 6.5% or greater (e.g. as assessed in accordance with “Use of glycated haemoglobin (HbA1c) in diagnosis of diabetes mellitus; Abbreviated report of a WHO consultation; 13 January 2011”).The subject may have a body mass index of 20 or greater, e.g. 21 or greater, 22 or greater, 23 or greater, or 24 or greater; preferably 25 or greater, 26 or greater, 27 or greater, 28 or greater, 29 or greater or 30 or greater. The subject is preferably overweight or obese.

[0049] The GLP-1 receptor agonist may be administered with a further therapeutic agent, or as a monotherapy. Further therapeutic agents may be selected from antidiabetic agents, antiobesity agents, appetite-regulating agents, anti-hypertensive agents, sulphonyl ureas, thiazolidinediones, biguanides, meglitinides, glucosidase inhibitors, glucagon antagonists, and OPP-IV (dipeptidyl peptidase-IV) inhibitors. In one embodiment, the further therapeutic agent is insulin.

[0050] The term “subject” generally refers to a vertebrate subject, and more particularly a mammalian subject. Suitable vertebrate animals include, but are not restricted to, primates, avians, livestock animals (e.g., sheep, cows, horses, donkeys, pigs), laboratory test animals (e.g., rabbits, mice, rats, guinea pigs, hamsters), companion animals (e.g., cats, dogs) and captive wild animals (e.g., foxes, deer, dingoes). A preferred subject is a human.

[0051] Accord to the invention, there is also provided a method of treating or preventing a disorder (preferably those outlined above) in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a GLP-1 receptor agonist, wherein said administering is performed via inhalation using a soft mist inhaler.

[0052] The subject is preferably as outlined above, and may have, or be at risk of, a metabolic disorder, a cardiovascular disorder, a neurodegenerative disorder, kidney disease or cancer (e.g. obesity-related cardiovascular disorders, neurodegenerative disorders, kidney diseases or cancers); preferably a metabolic disorder; preferably those outlined above.

[0053] Pharmaceutical composition

[0054] According to the invention, the pharmaceutical composition comprising the GLP-1 receptor agonist may further comprise at least one pharmaceutically acceptable excipient. The excipient may be selected from disodium phosphate dihydrate, propylene glycol, phenol, hydrochloric acid, sodium hydroxide, and water. Preferably, all of the aforementioned excipients are present.

[0055] Further suitable excipients would be known to the skilled person and are described, e.g., in standard pharmacopoeias such as U.S.P. or Ph. Eur., or in the Handbook of PharmaceuticalExcipients, 9th ed. Sheskey et al., Eds.; The Pharmaceutical Press and the American Pharmaceutical Association: 2020. In further specific embodiments, the pharmaceutical composition may further comprise one or more preservatives and / or antioxidants.

[0056] In other preferred embodiments, the pharmaceutical composition comprising the GLP-1 receptor agonist comprises a buffering agent, a salt, a surfactant and a preservative (and may consist of the foregoing). The buffering agent is preferably tr / s(hydroxymethyl)aminomethane (Tris) (e.g. Tris-HCI), the salt is preferably NaCI, the surfactant is preferably polysorbate 80 and the preservative is preferably ethylenediaminetetraacetic acid (EDTA) (e.g. Na-EDTA).

[0057] The pharmaceutical composition may comprise or consist of a GLP-1 receptor agonist, a buffering agent at from 1 to 20 mM (e.g. from 2 to 18 mM, from 3 to 17 mM, from 4 to 16 mM, from 5 to 15 mM, from 6 to 14 mM, from 7 to 13 mM, from 8 to 12 mM, from 9 to 11 mM, about 10 mM or 10mM), a salt at from 0.1 to 1.0% w / v (e.g. from 0.2 to 1.0% w / v, from 0.3 to 1.0% w / v, from 0.4 to 1.0% w / v, from 0.5 to 1.0% w / v, from 0.6 to 0.9% w / v, from 0.6 to 0.8% w / v, about 0.7% w / v, or 0.7% w / v), a surfactant at from 0.001 to 0.10% w / v (e.g. from 0.005 to 0.015% w / v, from 0.006 to 0.014% w / v, from 0.007 to 0.013% w / v, from 0.008 to 0.012% w / v, from 0.009 to 0.011 % w / v, about 0.01 % w / v, or 0.01 % w / v), and a preservative at from 0.001 % w / v to 0.01% w / v (e.g. from 0.001% to 0.009% w / v, from 0.002% to 0.008% w / v, from 0.003% to 0.007% w / v, from 0.004% to 0.006% w / v, about 0.005% w / v, or 0.005% w / v). The GLP-1 receptor agonist may be present in the composition at from 10 to 100 mg / ml (e.g. from 20 to 80 mg / ml, from 20 to 70 mg / ml, from 30 to 60 mg / ml, from 40 to 50 mg / ml, from 42 to 48 mg / ml, from 43 to 47 mg / ml, from 44 to 46 mg / ml, about 45 mg / ml or 45 mg / ml).

[0058] In preferred embodiments, the pharmaceutical composition comprises or consists of semaglutide, Tris (e.g. Tris HCI) at from 1 to 20 mM (e.g. from 2 to 18 mM, from 3 to 17 mM, from 4 to 16 mM, from 5 to 15 mM, from 6 to 14 mM, from 7 to 13 mM, from 8 to 12 mM, from 9 to 11 mM, about 10 mM or 10mM), NaCI at from 0.1 to 1.0% w / v (e.g. from 0.2 to 1.0% w / v, from 0.3 to 1.0% w / v, from 0.4 to 1.0% w / v, from 0.5 to 1.0% w / v, from 0.6 to 0.9% w / v, from 0.6 to 0.8% w / v, about 0.7% w / v, or 0.7% w / v), Polysorbate 80 at from 0.001 to 0.10% w / v (e.g. from 0.005 to 0.015% w / v, from 0.006 to 0.014% w / v, from 0.007 to 0.013% w / v, from 0.008 to 0.012% w / v, from 0.009 to 0.011% w / v, about 0.01% w / v, or 0.01% w / v), and EDTA (e.g. Na EDTA) at from 0.001% w / v to 0.01% w / v (e.g. from 0.001% to 0.009% w / v, from 0.002% to 0.008% w / v, from 0.003% to 0.007% w / v, from 0.004% to 0.006% w / v, about 0.005% w / v, or 0.005% w / v). Semaglutide may be present at from 10 to 100 mg / ml (e.g. from 20 to 80 mg / ml, from 20 to 70 mg / ml, from 30 to 60 mg / ml, from 40 to 50 mg / ml, from 42 to 48 mg / ml, from 43 to 47 mg / ml, from 44 to 46 mg / ml, about 45 mg / ml or 45 mg / ml). In a specific,preferred embodiment, the pharmaceutical composition comprises or consists of semaglutide at about 45 mg / ml, Tris HCI at about 10mM, NaCI at about 0.7% w / v, Polysorbate 80 at about 0.01% w / v, and Na-EDTA at about 0.005% w / v. In a specific, preferred embodiment, the pharmaceutical composition comprises or consists of semaglutide at 45 mg / ml, Tris HCI at 10mM, NaCI at 0.7% w / v, Polysorbate 80 at 0.01% w / v, and Na-EDTA at 0.005% w / v. As shown in the examples (see, e.g. Example 3), such pharmaceutical compositions exhibit good stability following storage at 2-8°C or 25°C, for at least three months. Furthermore, achieving a high strength formulation of 45 mg / ml semaglutide is, in itself, surprising, and generally unexpected for an inhaled peptide therapeutic, and allows for the delivery of therapeutically relevant doses

[0059] In a preferred embodiment, the pharmaceutical composition is clear and lacks perceptible colour, optionally following storage at 25°C or 2-8°C, optionally for at least one month, further optionally for at least three months.

[0060] In a preferred embodiment, the impurity content of the pharmaceutical composition is less than 2%, as assessed via reverse-phase high performance liquid chromatography (e.g. in accordance with Example 3b) , optionally following storage at 25°C or 2-8°C, optionally for at least one month, further optionally for at least three months.

[0061] In a preferred embodiment, the monomer content of the GLP-1 receptor agonist (preferably semaglutide) in the pharmaceutical composition is greater than: 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6% 99.7% or 99.8%, as assessed via size exclusion high performance liquid chromatography (e.g. in accordance with Example 3c), optionally following storage at 25°C or 2-8°C, optionally for at least one month, further optionally for at least three months.

[0062] The pH of the pharmaceutical composition may be from 7 to 8, from 7.2 to 7. 8, or from 7.3 to 7.5. Preferably, the pH is about 7.4, or is 7.4.

[0063] Alternatively, the GLP-1 receptor agonist (preferably semaglutide) may be present in the pharmaceutical composition at a concentration from 0.1 to 5 mg / ml, from 0.5 to 4 mg / ml, from 1 to 3 mg / ml, from 1 to 2 mg / ml, or preferably from 1.25 to 1.5 mg / ml. In such embodiments, more preferably, the GLP-1 receptor agonist (preferably semaglutide) is present in the pharmaceutical composition at a concentration of about 1.34 mg / ml, or 1.34 mg / ml.

[0064] The pharmaceutical composition is generally in liquid form.Preferably, the pharmaceutical composition lacks any perceptible unpleasant odour (e.g. following administration).

[0065] Following administration, the pharmaceutical composition will be aerosolised (i.e. in the form of an aerosolised liquid pharmaceutical composition). As used herein, “aerosolised liquid” or “aerosol” means that the pharmaceutical composition is present in the form of finely divided particles or droplets dispersed in air or another propellant as the continuous phase. As used herein, an “aerosolised liquid” has preferably not been generated by a nebuliser. As used herein, “following administration” refers to the properties of the pharmaceutical composition immediately upon expulsion from the inhalation device (e.g. the soft mist inhaler). Said properties will generally be maintained as the pharmaceutical composition travels into the pulmonary system of the subject.

[0066] When aerosolised (e.g. following administration), the percentage volume of droplets with a diameter < 5 pm in the pharmaceutical composition may be 50% or greater, 51% or greater, 52% or greater, 53% or greater, 54% or greater. When aerosolised (e.g. following administration), the percentage volume of droplets with a diameter < 5 pm in the pharmaceutical composition may be from 50% to 80%, from 50% to 70%, from 50% to 60%, or preferably from 50% to 55%. When aerosolised (e.g. following administration), the percentage volume of droplets with a diameter < 5 pm in the pharmaceutical composition may be 89% or greater, 90% or greater, or 91% or greater. When aerosolised (e.g. following administration), the percentage volume of droplets with a diameter < 5 pm in the pharmaceutical composition may be from 80% to 100%, 85% to 100%, 90% to 100%, or 90% to 95%. Preferably, the percentage volume of droplets with a diameter of < 5 pm or <10 pm in the composition is assessed via droplet size distribution (DSD) using laser diffraction. More preferably, said DSD is assessed via droplet size distribution using laser diffraction in accordance with Example 1.

[0067] When aerosolised (e.g. following administration), the percentage volume of droplets with a diameter < 5 pm in the pharmaceutical composition may be 20% or greater following storage at 2-8°C for at least one month. When aerosolised (e.g. following administration), the percentage volume of droplets with a diameter < 5 pm in the pharmaceutical composition may be 30% or greater following storage at 25°C for at least one month. Preferably, said assessment is made via DSD using laser diffraction. More preferably, said DSD is assessed using laser diffraction in accordance with Example 1 or 3e.When aerosolised (e.g. following administration), the percentage volume of droplets with a diameter < 5 pm in the pharmaceutical composition may be 45% or greater following storage at 2-8°C for at least three months. When aerosolised (e.g. following administration), the percentage volume of droplets with a diameter < 5 pm in the pharmaceutical composition may be 45% or greater following storage at 25°C for at least three months. Preferably, said assessment is made via DSD using laser diffraction. More preferably, said DSD is assessed using laser diffraction in accordance with Example 1 or 3e.

[0068] When aerosolised (e.g. following administration), the aerodynamic particle size distribution of particles in the pharmaceutical composition may be greater than 50% FPF, greater than 55% FPF, greater than 60% FPF, greater than 65% FPF, or greater than 70% FPF; wherein FPF is the fine particle fraction (droplets with a diameter of < 5 pm). When aerosolised (e.g. following administration), the aerodynamic particle size distribution of particles in the pharmaceutical composition may be from 50% to 80% FPF, from 50% to 70% FPF, from 60% to 70% FPF, or from 60% to 65% FPF; wherein FPF is the fine particle fraction (droplets with a diameter of < 5 pm). Preferably, said aerodynamic particle size distribution is assessed using a next generation impactor (NGI).

[0069] When aerosolised (e.g. following administration), the aerodynamic particle size distribution of particles in the pharmaceutical composition may be greater than 28% FPF following storage at 2-8°C for at least one month; wherein FPF is the fine particle fraction (droplets with a diameter of < 5 pm). When aerosolised (e.g. following administration), the aerodynamic particle size distribution of particles in the pharmaceutical composition may be greater than 34% FPF following storage at 25°C for at least one month; wherein FPF is the fine particle fraction (droplets with a diameter of < 5 pm). Preferably, said aerodynamic particle size distribution is assessed using a next generation impactor (NGI), e.g. in accordance with Example 3d.

[0070] When aerosolised (e.g. following administration), the aerodynamic particle size distribution of particles in the pharmaceutical composition may be greater than 30% FPF following storage at 2-8°C for at least three months; wherein FPF is the fine particle fraction (droplets with a diameter of < 5 pm). When aerosolised (e.g. following administration), the aerodynamic particle size distribution of particles in the pharmaceutical composition may be greater than 23% FPF following storage at 25°C for at least three months; wherein FPF is the fine particle fraction (droplets with a diameter of < 5 pm). Preferably, said aerodynamic particle size distribution is assessed using a next generation impactor (NGI), e.g. in accordance with Example 3d.When aerosolised (e.g. following administration), the pharmaceutical composition comprises respirable particles or droplets preferably having a mass median aerodynamic diameter (preferably as measured by laser diffraction) of not more than about 10 pm, in particular not more than about 7 pm, or not more than about 5 pm, respectively.

[0071] In an additional aspect of the invention, there is provided an inhalable pharmaceutical composition comprising or consisting of a GLP-1 receptor agonist, a buffering agent, a salt, a surfactant and a preservative. The buffering agent is preferably tr / s(hydroxymethyl)aminomethane (Tris) (e.g. Tris-HCI), the salt is preferably NaCI, the surfactant is preferably polysorbate 80 and the preservative is preferably ethylenediaminetetraacetic acid (EDTA) (e.g. Na-EDTA). The pharmaceutical composition may comprise or consist of a GLP-1 receptor agonist, a buffering agent at from 1 to 20 mM (e.g. from 2 to 18 mM, from 3 to 17 mM, from 4 to 16 mM, from 5 to 15 mM, from 6 to 14 mM, from 7 to 13 mM, from 8 to 12 mM, from 9 to 11 mM, about 10 mM or 10mM), a salt at from 0.1 to 1.0% w / v (e.g. from 0.2 to 1.0% w / v, from 0.3 to 1.0% w / v, from 0.4 to 1.0% w / v, from 0.5 to 1.0% w / v, from 0.6 to 0.9% w / v, from 0.6 to 0.8% w / v, about 0.7% w / v, or 0.7% w / v), a surfactant at from 0.001 to 0.10% w / v (e.g. from 0.005 to 0.015% w / v, from 0.006 to 0.014% w / v, from 0.007 to 0.013% w / v, from 0.008 to 0.012% w / v, from 0.009 to 0.011% w / v, about 0.01% w / v, or 0.01% w / v), and a preservative at from 0.001% w / v to 0.01% w / v (e.g. from 0.001 % to 0.009% w / v, from 0.002% to 0.008% w / v, from 0.003% to 0.007% w / v, from 0.004% to 0.006% w / v, about 0.005% w / v, or 0.005% w / v). The GLP-1 receptor agonist may be present in the composition at from 10 to 100 mg / ml (e.g. from 20 to 80 mg / ml, from 20 to 70 mg / ml, from 30 to 60 mg / ml, from 40 to 50 mg / ml, from 42 to 48 mg / ml, from 43 to 47 mg / ml, from 44 to 46 mg / ml, about 45 mg / ml or 45 mg / ml). In preferred embodiments, the pharmaceutical composition comprises or consists of semaglutide, Tris (e.g. Tris HCI) at from 1 to 20 mM (e.g. from 2 to 18 mM, from 3 to 17 mM, from 4 to 16 mM, from 5 to 15 mM, from 6 to 14 mM, from 7 to 13 mM, from 8 to 12 mM, from 9 to 11 mM, about 10 mM or 10mM), NaCI at from 0.1 to 1.0% w / v (e.g. from 0.2 to 1.0% w / v, from 0.3 to 1.0% w / v, from 0.4 to 1.0% w / v, from 0.5 to 1.0% w / v, from 0.6 to 0.9% w / v, from 0.6 to 0.8% w / v, about 0.7% w / v, or 0.7% w / v), Polysorbate 80 at from 0.001 to 0.10% w / v (e.g. from 0.005 to 0.015% w / v, from 0.006 to 0.014% w / v, from 0.007 to 0.013% w / v, from 0.008 to 0.012% w / v, from 0.009 to 0.011% w / v, about 0.01% w / v, or 0.01% w / v), and EDTA (e.g. Na EDTA) at from 0.001% w / v to 0.01% w / v (e.g. from 0.001% to 0.009% w / v, from 0.002% to 0.008% w / v, from 0.003% to 0.007% w / v, from 0.004% to 0.006% w / v, about 0.005% w / v, or 0.005% w / v). Semaglutide may be present at from 10 to 100 mg / ml (e.g. from 20 to 80 mg / ml, from 20 to 70 mg / ml, from 30 to 60 mg / ml, from 40 to 50 mg / ml, from 42 to 48 mg / ml, from 43 to 47 mg / ml, from 44 to 46mg / ml, about 45 mg / ml or 45 mg / ml). In a specific, preferred embodiment, the pharmaceutical composition comprises or consists of semaglutide at 45 mg / ml, Tris HCI at 10mM, NaCI at 0.7% w / v, Polysorbate 80 at 0.01% w / v, and Na-EDTA at 0.005% w / v. The pharmaceutical composition may be contained within a soft mist- inhaler, or as part of a kit further comprising a soft mist inhaler

[0072] Inhalation device / soft mist inhaler / kit

[0073] The term “inhalation device” as used herein is to be understood in the broadest sense as referring to a device that allows and is adapted for the aerosolisation in inhalative administration, preferably by oral inhalation, of a pharmaceutical composition. A soft mist inhaler (SMI) is a handheld inhalation device that delivers medication to the lungs by converting a liquid pharmaceutical composition into a mist. The mist is generally fine and slow moving. Unlike traditional inhalers, SMIs do not use propellants; instead, they rely on mechanical energy to generate the aerosol.

[0074] Advantageously, unlike conventional inhalers, the patient does not have to do a sudden inbreath to administer the medication effectively, and therefore SMIs present a distinct advantage for patients who have respiratory issues, such as those associated with obesity, for example breathlessness. This is at least in part due to the slow moving speed of the generated mist, and duration of administration (~1.5s) of an SMI.

[0075] Components of the inhalation device for generating an aerosolised liquid pharmaceutical composition, according to the invention, are a housing having a user-facing side; at least one impingement-type nozzle for generating the aerosol by collision of at least two liquid jets, the nozzle being firmly affixed to the user-facing side of the housing such as to be immobile relative to the housing; a fluid reservoir, in which the pharmaceutical composition that is to be aerosolised is contained, arranged within the housing; and a pumping unit arranged within the housing, for generation of a pressure being sufficiently high for aerosolisation.

[0076] Inhalation devices according to the invention are described in patent applications PCT / EP2018 / 061056, and PCT / EP2019 / 068866, the contents of which are incorporated herein in their entirety.

[0077] Inhalation devices as described above have proven as a very effective means for providing pharmaceutical compositions contained therein into the lungs of a patient or subject in need thereof.The at least one impingement-type nozzles may be adapted to emit at least two jets of liquid which are directed such as to collide and break up into small aerosol droplets of the pharmaceutical composition to aerosolised. The nozzle or nozzles usually are firmly affixed to the user-facing side of the housing of the inhalation device in such a way that it is immobile, or non-moveable, relative to the housing or at least relative to the side or part of the housing which faces the user (e.g., patient) when the device is used. Preferably, there is a plurality of impingement-type nozzles.

[0078] The at least one impingement-type nozzle(s) may be microstructured nozzles, comprising a plurality of channels each having a cross section in the order of several square micrometres (pm2), such as from 1 pm2to 200 pm2, 2 pm2to 200 pm2, 2 pm2to 100 pm2, 5 pm2to 50 pm2, or 10 pm2to 25 pm2. Microstructured nozzles enable the device to a sufficiently homogenous and fine mist of liquid droplets at relatively high pressures, whilst also keep the amount of vaporized liquid for each dose acceptably low.

[0079] By means of the pumping device, the liquid is drawn in a discrete amount, i.e., not continuously, from the reservoir, and fed to the nozzle. The pumping device may work without propellant and may generate pressure mechanically.

[0080] In preferred embodiments, the inhalation device is essentially free of a propellant, such as a hydrofluoroalkane (HFA) propellant.

[0081] Advantageously, SMIs are typically propellant free and do not require harmful chemical propellants, making them more environmentally friendly. Additionally, SMIs generate a fine, slow-moving mist, and as the aerosol is gentle and slow, there is typically reduced throat irritation and coughing compared to alternative inhaler therapies, such as metered-dose inhalers (MDIs) or dry powder inhalers (DPIs). SMIs have been shown to provide improved lung deposition, because the slow mist allows a greater amount of the administered pharmaceutical composition to reach the lungs, with less being deposited in the mouth and throat. SMIs are also favourable due to their ease of use, as they typically require less coordination between actuation and inhalation, making them suitable for patients who may struggle with timing or have weak inspiratory flow.

[0082] The means for storing potential energy may be selected from a tension spring, a pressure spring, a magnetic force utilising material or a gaseous medium. When the means for storing potential energy is a gaseous medium, it is preferably a compressed inert or non-toxic gas.Preferably, the means for storing potential energy is a mechanical means, such as for example a tension spring, a pressure spring, or a magnetic force utilising material. By (preferably manually) loading the spring, potential energy is stored in the inhalation device. The energy can subsequently be used for generating a pressure inside the pumping unit which is fluidically connected to the nozzle.

[0083] Advantageously, the inhalation device is generally propellant-free, using mechanical power, typically a spring mechanism, to deliver the pharmaceutical composition as a fine mist. This means they do not rely on chemical propellants (such as hydrofluoroalkanes used in pressurized metered-dose inhalers) to generate the aerosol. Instead, the device pushes the pharmaceutical composition through specially engineered nozzles, creating a slow-moving, inhalable mist.

[0084] The absence of propellants in inhalation devices according to the invention offers several advantages. First, there are environmental benefits, as propellant-free devices significantly reduce greenhouse gas emissions compared to traditional propellant-based inhalers. Secondly, mechanical means enable more consistent dosing, as mechanical actuation ensures reliable, reproducible dosing and particle size, independent of patient inhalation strength. Thirdly, there are patient and clinical benefits, in that the slow mist generated improves lung deposition and reduces medication loss in the mouth and throat, often allowing for lower doses without sacrificing efficacy.

[0085] By using mechanical power to generate the pressure inside the pumping unit, no premature pumping of liquid occurs, and therefore no liquid is emitted prior to the actual dosing. No clogging of the nozzle exits due to pre-emission of liquid takes place, avoiding undesired droplet formation, and a generation of splashes. As a result, the overall number of possible dosing cycles per reservoir is increased.

[0086] In some embodiments, a blocking means may be provided to prevent unintentional actuation of the device, resulting in decreased production and assembly costs as well as an decreased probability of mechanical failure.

[0087] Advantageously, the inhalation device according to the invention is able to prevent any premature and undesired release of liquid from the nozzle, as well as avoid a reduction of dosing cycles per reservoir. Thus, the inhalation device provides enhanced dosing precision relative to devices known in the art. Additionally, the device provides a cost effective and mechanically reliable solution.In some embodiments of the invention, the inhalation device may comprise a dose counter. Advantageously, the inclusion of a built-in dose counter and lock when empty, provides clear feedback to users.

[0088] The fluid reservoir may be a removable and / or replaceable cartridge.

[0089] Inhalation devices and the cartridges therefor have a finite lifetime. Maintaining effective actuations throughout the lifetime of use is essential for maintaining effective dosing and thus, therapy of the subject.

[0090] Inhalation devices and cartridges therefor according to the invention preferably maintain their dosing across their lifetime.

[0091] When aerosolised (e.g. following administration), the percentage volume of droplets produced by the inhalation device at the device and / or cartridge end of life with a diameter < 5 pm in the pharmaceutical composition may be 40% or greater, 45% or greater, 50% or greater, 52% or greater, or 54% or greater. When aerosolised (e.g. following administration), the percentage volume of droplets produced by the inhalation device at the device and / or cartridge end of life with a diameter < 5 pm in the pharmaceutical composition may be from 40% to 60%, from 45% to 55%, or preferably from 50% to 55%.

[0092] When aerosolised (e.g. following administration), the percentage volume of droplets produced by the inhalation device at the device and / or cartridge end of life with a diameter < 10 pm in the pharmaceutical composition may be 89% or greater, 90% or greater, or 91% or greater. When aerosolised (e.g. following administration), the percentage volume of droplets produced by the inhalation device at the device and / or cartridge end of life with a diameter < 10 pm in the pharmaceutical composition may be from 80% to 100%, 85% to 100%, 90% to 100%, or 90% to 95%.

[0093] Preferably, the percentage volume of droplets produced by the inhalation device at the device and / or cartridge end of life with a diameter of < 5 pm or <10 pm in the composition is assessed via droplet size distribution (DSD) using laser diffraction. More preferably, said DSD is assessed via droplet size distribution using laser diffraction in accordance with Example 1. “End of life” as used herein may be defined as 55 or more, 56 or more, 57 or more, 58 or more, 59 or more, or 60 or more actuations.In embodiments of the invention, the decrease in the percentage volume of droplets with a diameter < 5 pm or < 10 pm in the pharmaceutical composition over the lifetime of the device or cartridge may be less than 10 %, less than 8%, less than 6%, less than 4%, or less than 2%. Preferably, the decrease in the percentage volume of droplets with a diameter < 5 pm or < 10 pm in the pharmaceutical composition over the lifetime of the device or cartridge may be less than 4 %, or less than 2%. In doing so, the inhalation devices or cartridges therefor according to the invention maintain a favourable droplet size distribution for a longer time than alternative devices or cartridges (e.g. periods of -100 days).

[0094] According to the invention, there is also provided a kit comprising an inhalation device; and an inhalable pharmaceutical composition comprising a GLP-1 receptor agonist; wherein the pharmaceutical composition is contained within a cartridge. The cartridge may be replaceable. The cartridge may be loadable into the device, or pre-loaded into the device

[0095] Advantageously, providing the inhalation device as a kit, with e.g. a replaceable cartridge, enables the user themselves to replace an exhausted cartridge and extend the lifetime of the inhaler device, which provides improved sustainability.

[0096] In some embodiments the cartridge may have a volume of 10 pl, 15 pl, 25 pl, 30 pl, 40 pl, or 50 pl, or alternatively a volume from 10 pl to 50 pl, 15 pl to 40 pl, or from 15 pl to 25 pl.

[0097] Advantageously, the inhalation device according to the invention is able to hold different volumes of cartridge. By having the ability to use a cartridge that is able to hold different volumes of pharmaceutical composition, the device is versatile for a broad dosing range, enabling long term administration to subjects.

[0098] Advantageously, cartridges for inhalation devices according to the invention may be compatible with ethanol, allowing non-aqueous pharmaceutical compositions to be administered.

[0099] Referring to Figure 1, there is shown a schematic illustration of an example inhalation device according to the invention, prior to its first use, i.e. prior to any device actuation. The inhalation device comprises a housing (1), which is preferably shaped and dimensioned such that it can be held with one hand and can be operated by one finger, e.g., a thumb or index finger.

[0100] A fluid reservoir (2) for the storage of the pharmaceutical composition (F) to be administered according to the present invention is located inside the housing (1). The reservoir (2) may bedesigned to be collapsible so that in the course of the emptying of the reservoir by the repeated use of the device, the soft or elastic walls deform such that the negative pressure required for withdrawing liquid from the reservoir remains substantially constant over time.

[0101] Further, the inhalation device comprises a pumping unit with a hollow cylinder (9) within the housing (1) which forms a pumping chamber (3) for the generation of the desired pressure which is necessary for emitting the pharmaceutical composition (F) and aerosolising the same. The pumping unit may also comprise further components not depicted in the figure, such as a push button, locking device, etc. A means for the storage of potential energy (7), in the form of a spring is shown which is coupled with one end (upwards directed, or downstream) to the cylinder (9) and which is supported at the housing (1).

[0102] The inhalation device further comprises a riser pipe (5) with at least one reservoir-facing, or upstream, interior end (5A) which can be received in said cylinder (9). In other words, the riser pipe (5) can be at least partially pushed into hollow cylinder (9), resulting in a decrease of the interior volume of pumping chamber (3). The term “interior volume” describes the volume of the space which extends from the reservoir-facing inlet of the cylinder (9) to the place where the interior end (5A) of the riser pipe (5) is located. In the depicted situation, riser pipe (5) is almost entirely contained in the cylinder (9). As a result, the interior volume of the pumping chamber (3), situated between inlet valve (4) and the interior end (5A) of riser pipe (5), is at a minimum.

[0103] Preferably, the section (or segment) of the hollow cylinder (9) which serves as, or accommodates, the pumping chamber (3) and which receives the riser pipe (5) exhibits a circular inner cross-section whose diameter relatively closely (e.g., except for a small gap) matches the diameter of the circular outer cross-section of the corresponding segment of the riser pipe (5).

[0104] In the embodiment illustrated by Figure 1, the inlet valve (4) is arranged between reservoir (2) and inlet of the pumping chamber (3) formed by the cylinder (9). Also depicted is an optional outlet valve (8) inside the riser pipe (5) for avoiding a backflow of liquid or air into the exterior end (5B) of the same from the outside. Outlet valve (8) is arranged in the interior end (5A) of riser pipe (5). The pharmaceutical composition (F) can pass outlet valve (8) in direction of nozzle (6), but outlet valve (8) blocks any undesired backflow in the opposite direction.The inhalation device comprises a nozzle (6) which is connected liquid-tight to the exterior (or downstream) end (5B) of the riser pipe (5). Nozzle (6) is an impingement-type nozzle for generating the aerosol by collision of at least two liquid jets.

[0105] The riser pipe (5) is designed immobile with respect to the housing (1), and firmly attached to housing (1), indicated by the connection in the region of exterior end (5B) with housing (1). Riser pipe (5) is also firmly attached to nozzle (6), which, in turn, is attached to housing (1) as well. In contrast, the hollow cylinder (9) providing the pumping chamber (3) is designed to be moveable with respect to housing (1) and nozzle (6).

[0106] Referring to Figure 2, there is shown a device similar to the one of Figure 1 without the (optional) outlet valve (8). All other components are present, and also the function is comparable. In this embodiment, pumping chamber (3) extends from downstream of the valve (4) up to nozzle (6), which is the location where the fluidic resistance increases significantly.

[0107] Referring to Figure 3, there is shown the embodiment of Figure 1 with a filled pumping chamber. The hollow cylinder (9) has been moved to its most upstream position, thereby loading the means for the storage of potential energy (7). Outlet valve (8) is closed due to negative pressure inside pumping chamber (3), and the inlet valve (4) is open towards the fluid reservoir (2). Increasingly collapsing walls of reservoir (2) allow the internal pressure in the reservoir (2) to remain nearly constant, while the pressure inside the pumping chamber (3) drops because of the propulsive longitudinal motion of the hollow cylinder (9), thus increasing the volume of pumping chamber (3). As a result, the pumping chamber (3) has been filled with the pharmaceutical composition (F) from the reservoir (2).

[0108] Referring to Figure 4, there is shown the situation after the first actuation of the inhalation device of Figure 1. The means for the storage of potential energy (7) has been released from the loaded position as shown in Figure 3. It pushes the cylinder (9) in a downstream direction such as to slide over the riser pipe (5). The interior end (5A) of the riser pipe (5) has come closer to the inlet check valve (4) which is now closed. As a result, the pressure inside the pumping chamber (3) rises and keeps the inlet valve (4) closed but opens outlet valve (8). Pharmaceutical composition (F) flows from the riser pipe (5) through its exterior end (5B) towards nozzle (6).

[0109] Referring to Figure 5, there is shown the inhalation device of Figure 1 at the end of the aerosol emission phase. The means for the storage of potential energy (7) is in its most relaxed end position (spring fully extended). Also, the hollow cylinder (9) has been pushed almost entirelyonto riser pipe (5) such that the interior volume of pumping chamber (3) has reached its minimum. Most of the pharmaceutical composition (F) previously contained in the pumping chamber (3) has passed outlet valve (8) into the main segment of the riser pipe (5). Some pharmaceutical composition (F) has been pushed towards, and though, nozzle (6), where aerosolisation takes place, such that an aerosol is emitted towards the user or patient.

[0110] Referring to Figure 6, there is shown the inhalation device of Figure 1 after re-filling the pumping chamber. The hollow cylinder (9) has been moved (repulsively) in an upstream direction, thus increasing the volume of the pumping chamber (3) provided by the cylinder (9). The means for the storage of potential energy (7) has been loaded (spring compressed). During movement of cylinder (9) away from the nozzle (6), a negative pressure has been generated in the pumping chamber (3), closing outlet valve (8) and opening the inlet check valve 4. As a result, further pharmaceutical composition (F) is drawn from reservoir (2) into the pumping chamber (3). The inhalation device’s pumping chamber (3) is filled again and ready for the next ejection of pharmaceutical composition (F) by releasing the spring.

[0111] EMBODIMENTS

[0112] The present invention also provides the following numbered embodiments. Combinations of features outlined below are exemplary, and not to be construed as exhaustive.

[0113] Embodiment 1. An inhalable pharmaceutical composition comprising a GLP-1 receptor agonist, for use in the therapy of a subject; said therapy comprising administering the composition to the subject via a soft mist inhaler.

[0114] Embodiment 2. The inhalable pharmaceutical composition for use according to embodiment 1, wherein the GLP-1 receptor agonist is selected from semaglutide, liraglutide, exenatide, lixisenatide, dulaglutide, albiglutide, beinaglutide, PEG-loxenatide, tirzepatide, ASC30 and multi-agonist incretin peptides (e.g. dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonists, and triple GLP-1, GIP and glucagon agonists, e.g. retatrutide).

[0115] Embodiment 3. The inhalable pharmaceutical composition for use according to embodiment 2, wherein the GLP-1 receptor agonist is semaglutide.Embodiment 4. The inhalable pharmaceutical composition for use according to any one of embodiments 1 to 3, wherein the pH of the pharmaceutical composition is from 7 to 8, from 7.2 to 7. 8, or from 7.3 to 7.5; optionally wherein the pH is 7.4.

[0116] Embodiment 5. The inhalable pharmaceutical composition for use according to any one of embodiments 1 to 4, wherein the pharmaceutical composition comprises at least one additional excipient.

[0117] Embodiment 6. The inhalable pharmaceutical composition for use according to embodiment 5, wherein the additional excipients are selected from disodium phosphate dihydrate, propylene glycol, phenol, hydrochloric acid, sodium hydroxide, and water.

[0118] Embodiment 7. The inhalable pharmaceutical composition for use according to embodiment 6, wherein all the additional excipients are present.

[0119] Embodiment 8. The inhalable pharmaceutical composition for use according to embodiment 5, wherein the excipients are a buffering agent, a salt, a surfactant and a preservative; optionally wherein the composition consists of the GLP-1 receptor agonist, in addition to the foregoing excipients.

[0120] Embodiment 9. The inhalable pharmaceutical composition for use according to embodiment 8, wherein the pharmaceutical composition comprises or consists of a buffering agent at from 1 to 20 mM, from 2 to 18 mM, from 3 to 17 mM, from 4 to 16 mM, from 5 to 15 mM, from 6 to 14 mM, from 7 to 13 mM, from 8 to 12 mM, from 9 to 11 mM, about 10 mM or 10mM; a salt at from 0.1 to 1.0% w / v, from 0.2 to 1.0% w / v, from 0.3 to 1.0% w / v, from 0.4 to 1.0% w / v, from 0.5 to 1.0% w / v, from 0.6 to 0.9% w / v, from 0.6 to 0.8% w / v, about 0.7% w / v, or 0.7% w / v; a surfactant at from 0.001 to 0.10% w / v, from 0.005 to 0.015% w / v, from 0.006 to 0.014% w / v, from 0.007 to 0.013% w / v, from 0.008 to 0.012% w / v, from 0.009 to 0.011% w / v, about 0.01% w / v, or 0.01% w / v; and a preservative at from 0.001% w / v to 0.01% w / v, from 0.001% to 0.009% w / v, from 0.002% to 0.008% w / v, from 0.003% to 0.007% w / v, from 0.004% to 0.006% w / v, about 0.005% w / v, or 0.005% w / v; optionally wherein the pharmaceutical composition comprises the GLP-1 receptor agonist at from 10 to 100 mg / ml, from 20 to 80 mg / ml, from20 to 70 mg / ml, from 30 to 60 mg / ml, from 40 to 50 mg / ml, from 42 to 48 mg / ml, from 43 to 47 mg / ml, from 44 to 46 mg / ml, about 45 mg / ml or 45 mg / ml.

[0121] Embodiment 10. The inhalable pharmaceutical composition for use according to embodiment 5 or 8, wherein the excipients are Tris (e.g. Tris HCI), NaCI, Polysorbate 80 and EDTA (e.g. Na-EDTA); optionally wherein the composition consists of the GLP-1 receptor agonist, in addition to the foregoing excipients.

[0122] Embodiment 11. The inhalable pharmaceutical composition for use according to embodiment 10, wherein the pharmaceutical composition comprises or consists of Tris (e.g. Tris HCI) at from 1 to 20 mM, from 2 to 18 mM, from 3 to 17 mM, from 4 to 16 mM, from 5 to 15 mM, from 6 to 14 mM, from 7 to 13 mM, from 8 to 12 mM, from 9 to 11 mM, about 10 mM or 10mM; NaCI at from 0.1 to 1.0% w / v, from 0.2 to 1.0% w / v, from 0.3 to 1.0% w / v, from 0.4 to 1.0% w / v, from 0.5 to 1.0% w / v, from 0.6 to 0.9% w / v, from 0.6 to 0.8% w / v, about 0.7% w / v, or 0.7% w / v; Polysorbate 80 at from 0.001 to 0.10% w / v, from 0.005 to 0.015% w / v, from 0.006 to 0.014% w / v, from 0.007 to 0.013% w / v, from 0.008 to 0.012% w / v, from 0.009 to 0.011 % w / v, about 0.01 % w / v, or 0.01 % w / v; and EDTA (e.g. Na-EDTA) at from 0.001 % w / v to 0.01 % w / v, from 0.001 % to 0.009% w / v, from 0.002% to 0.008% w / v, from 0.003% to 0.007% w / v, from 0.004% to 0.006% w / v, about 0.005% w / v, or 0.005% w / v; optionally wherein the pharmaceutical composition comprises semaglutide at from 10 to 100 mg / ml, from 20 to 80 mg / ml, from 20 to 70 mg / ml, from 30 to 60 mg / ml, from 40 to 50 mg / ml, from 42 to 48 mg / ml, from 43 to 47 mg / ml, from 44 to 46 mg / ml, about 45 mg / ml or 45 mg / ml.

[0123] Embodiment 12. The inhalable pharmaceutical composition for use according to any one of embodiments 1 to 7, wherein the GLP-1 receptor agonist is present in the pharmaceutical composition at a concentration from 0.1 to 5 mg / ml, from 0.5 to 4 mg / ml, from 1 to 3 mg / ml, from 1 to 2 mg / ml, or from 1.25 to 1.5 mg / ml; optionally wherein the GLP-1 receptor agonist is present in the pharmaceutical composition at a concentration of 1.34 mg / ml.Embodiment 13. The inhalable pharmaceutical composition for use according to any one of embodiments 1 to 12, wherein the therapy is of a disorder in a subject, wherein the disorder is selected from a metabolic disorder, a cardiovascular disorder, a neurodegenerative disorder, kidney disease and cancer.

[0124] Embodiment 14. The inhalable pharmaceutical composition for use according to embodiment 13, wherein the therapy is of a metabolic disorder in a subject.

[0125] Embodiment 15. The inhalable pharmaceutical composition for use according to embodiment 14, wherein the metabolic disorder is selected from obesity, type II diabetes, type I diabetes, hyperglycaemia, impaired glucose tolerance, non-alcoholic fatty liver disease, alcoholic fatty liver disease, cardiovascular disease and polycystic ovary syndrome.

[0126] Embodiment 16. The inhalable pharmaceutical composition for use according to embodiment 15, wherein the metabolic disorder is obesity.

[0127] Embodiment 17. The inhalable pharmaceutical composition for use according to embodiment 15, wherein the metabolic disorder is type II diabetes.

[0128] Embodiment 18. The inhalable pharmaceutical composition for use according to embodiment 15, wherein the metabolic disorder is hyperglycaemia.

[0129] Embodiment 19. The inhalable pharmaceutical composition for use according to embodiment 15, wherein the metabolic disorder is impaired glucose tolerance.

[0130] Embodiment 20. The inhalable pharmaceutical composition for use according to embodiment 16, for use in a method of reducing the body weight of the subject, a method of reducing food intake by the subject, or a method of inducing satiety in the subject.

[0131] Embodiment 21. The inhalable pharmaceutical composition for use according to any one of embodiments 1 to 20, wherein the composition is administered as an aerosol.Embodiment 22. The inhalable pharmaceutical composition for use according to either embodiment 21 or 22, wherein the aerosol is produced by at least one impingement-type nozzle for generating the aerosol by collision of at least two liquid jets.

[0132] Embodiment 23. The inhalable pharmaceutical composition for use according to any one of embodiments 1 to 22, wherein the soft mist inhaler is an inhalation device comprising:

[0133] a housing having a user-facing side;

[0134] at least one impingement-type nozzle for generating an aerosol by collision of at least two liquid jets, the nozzle being firmly affixed to the user-facing side of the housing such as to be immobile relative to the housing;

[0135] a fluid reservoir arranged within the housing; and

[0136] a pumping unit arranged within the housing,

[0137] wherein the fluid reservoir is adapted to hold the inhalable pharmaceutical composition from which the aerosol is generated by the inhalation device.

[0138] Embodiment 24. The inhalable pharmaceutical composition for use according any one of embodiments 1 to 23, wherein, following administration, the percentage volume of droplets with a diameter of < 5 pm in the composition is 50% or greater 51% or greater, 52% of greater, 53% or greater, 54% or greater, 55% or greater, 56% or greater, 57% or greater, 58% or greater, or 59% or greater.

[0139] Embodiment 25. The inhalable pharmaceutical composition for use according any one of embodiments 1 to 24, wherein, following administration, the percentage volume of droplets with a diameter of < 10 pm in the composition is 89% or greater, 90% or greater, or 91% or greater.

[0140] Embodiment 26. The inhalable pharmaceutical composition for use according any one of embodiments 1 to 23, wherein, following administration, the aerodynamic particle size distribution of particles in the composition is greater than 50% FPF, greater than 55% FPF, greater than 60% FPF, greater than 65% FPF, or greater than 70% FPF, wherein FPF is the fine particle fraction (droplets with a diameter of < 5 pm).Embodiment 27. An aerosolised liquid pharmaceutical composition comprising a GLP-1 receptor agonist.

[0141] Embodiment 28. The aerosolised liquid pharmaceutical composition according to embodiment 23, wherein the percentage volume of droplets with a diameter of < 5pm in the composition is 50% or greater 51% or greater, 52% of greater, 53% or greater, 54% or greater, 55% or greater, 56% or greater, 57% or greater, 58% or greater, or 59% or greater.

[0142] Embodiment 29. The aerosolised liquid pharmaceutical composition according to either embodiment 27 or 28, wherein the percentage volume of droplets with a diameter of < 10 pm in the composition is 89% or greater, 90% or greater, or 91% or greater.

[0143] Embodiment 30. The aerosolised liquid pharmaceutical composition according to embodiment 27, wherein the the aerodynamic particle size distribution of particles in the composition is greater than 50% FPF, greater than 55% FPF, greater than 60% FPF, greater than 65% FPF, or greater than 70% FPF, wherein FPF is the fine particle fraction (droplets with a diameter of < 5 pm).

[0144] Embodiment 31. The aerosolised liquid pharmaceutical composition according to any of embodiments 27-30, wherein the GLP1 -receptor agonist is as defined in any of embodiments 2-3.

[0145] Embodiment 32. The aerosolised liquid pharmaceutical composition according to any of embodiments 27-31 , wherein the composition has the features of any of embodiments 4-12.

[0146] Embodiment 33. The inhalable pharmaceutical composition according to embodiments 24 to 26, or the aerosolised liquid pharmaceutical composition according to embodiments 27 to 32, wherein the diameter and percentage volume of droplets is measured by droplet size distribution using laser diffraction.

[0147] Embodiment 34. An inhalation device for generating an aerosol, comprising:

[0148] a housing having a user-facing side;at least one impingement-type nozzle for generating the aerosol by collision of at least two liquid jets, the nozzle being firmly affixed to the userfacing side of the housing such as to be immobile relative to the housing; a fluid reservoir arranged within the housing; and

[0149] a pumping unit arranged within the housing,

[0150] wherein the fluid reservoir is adapted to hold an inhalable pharmaceutical composition from which the aerosol is generated by the inhalation device; wherein the fluid reservoir comprises an inhalable pharmaceutical composition comprising a GLP-1 receptor agonist.

[0151] Embodiment 35. A kit comprising:

[0152] an inhalation device; and

[0153] an inhalable pharmaceutical composition comprising a GLP-1 receptor agonist;

[0154] wherein the pharmaceutical composition is contained within a cartridge.

[0155] Embodiment 36. The kit according to embodiment 35, wherein the cartridge is loadable into the device, or pre-loaded into the device; optionally wherein the cartridge is replaceable.

[0156] Embodiment 37. A kit according to embodiment 35 or 36, wherein the inhalation device comprises:

[0157] a housing having a user-facing side;

[0158] at least one impingement-type nozzle for generating an aerosol by collision of at least two liquid jets, the nozzle being firmly affixed to the user-facing side of the housing such as to be immobile relative to the housing; and a pumping unit arranged within the housing;

[0159] and

[0160] wherein the cartridge is a fluid reservoir, wherein the fluid reservoir is adapted to hold the inhalable pharmaceutical composition from which the aerosol is generated by the inhalation device.

[0161] Embodiment 38. The inhalation device according to embodiment 34, or the kit according to embodiment 35 to 37, wherein the GLP-1 receptor agonist is as defined in embodiment 2 or 3.Embodiment 39. The inhalation device according to embodiment 34, or the kit according to embodiment 35 to 37, wherein pharmaceutical composition is as defined in any of embodiments 4-12.

[0162] Embodiment 40. The inhalable pharmaceutical composition for use according to any one of embodiments 24 to 27, the inhalation device according to embodiment 34- 39, or the kit according to embodiment 36-37, wherein the pumping unit further comprises:

[0163] a riser pipe having an upstream end, wherein the riser pipe is adapted to function as a piston in the pumping unit, and firmly affixed to the user-facing side of the housing such as to be immobile relative to the housing;

[0164] a hollow cylinder located upstream of the riser pipe, wherein the upstream end of the riser pipe is inserted in the cylinder such that the cylinder is longitudinally movable on the riser pipe; and

[0165] a lockable means for storing potential energy when locked and for releasing the stored energy when unlocked, the means being arranged outside of, and mechanically coupled to, the cylinder such that unlocking the means results in a propulsive longitudinal movement of the cylinder towards the downstream end of the pumping unit.

[0166] Embodiment 41. The pharmaceutical composition for use, inhalation device or kit according to embodiment 40, wherein the hollow cylinder is fluidically connected with the fluid reservoir, directly or indirectly.

[0167] Embodiment 42. The pharmaceutical composition for use, inhalation device or kit according to embodiment 40 or 41 , wherein the means for storing potential energy is selected from a tension spring, a pressure spring, a magnetic force utilising material or a gaseous medium.

[0168] Embodiment 43. The pharmaceutical composition for use, inhalation device or kit according to any of embodiments 40-42, wherein the pumping unit is a high-pressure pumping unit; and / or

[0169] the pumping unit is effective to expel fluid at a pressure of from 2 bar to 1000 bar, 10 bar to 250 bar, or 50 bar to 100 bar.Embodiment 44. The pharmaceutical composition for use or inhalation device according to any of embodiments 40-43, wherein the fluid reservoir is a cartridge, optionally wherein the cartridge is replaceable.

[0170] Embodiment 45. The pharmaceutical composition for use, inhalation device or kit according to any of embodiments 40-44, wherein the fluid reservoir has a capacity of from 100 pl to 5 mL of the pharmaceutical composition.

[0171] Embodiment 46. The pharmaceutical composition for use, inhalation device or kit according to any of embodiments 40-45, wherein the fluid is drawn in a discrete amount by the pumping unit in a single pumping cycle.

[0172] Embodiment 47. The pharmaceutical composition for use, inhalation device or kit according to any of embodiments 40-46, wherein the volume of fluid that drawn by the pumping unit in a single pumping cycle is from 0.1 to 1000 pl, 1 to 250 pl, or from 2 to 150 pl.

[0173] Embodiment 48. The pharmaceutical composition for use, inhalation device or kit according to any of embodiments 40-47, wherein the device is mechanically or electronically operated.

[0174] Embodiment 49. The pharmaceutical composition for use, inhalation device or kit according to any of embodiments 22-30, 34 or 37 to 48, wherein the at least one impingement-type nozzle(s) are microstructured nozzle(s); optionally wherein the microstructured nozzles comprise a plurality of channels each having a cross section from 1 pm2to 200 pm2, 2 pm2to 200 pm2, 2 pm2to 100 pm2, 5 pm2to 50 pm2, or 10 pm2to 25 pm2.

[0175] Embodiment 50. The pharmaceutical composition for use, inhalation device or kit according to any of embodiments 23-26 or 34 to 49, wherein the decrease in the percentage volume of droplets with a diameter < 5 pm or < 10 pm of the pharmaceutical composition produced over the lifetime of the device is less than 10 %, less than 8%, less than 6%, less than 4%, or less than 2%

[0176] Embodiment 51. The pharmaceutical composition for use, inhalation device or kit according to any of embodiments 23-26 or 34 to 50, wherein the decrease in the percentage volume of the pharmaceutical composition produced over thelifetime of the device is less than 10 %, less than 8%, less than 6%, less than 4%, or less than 2%.

[0177] Embodiment 52. A method of treating or preventing a disorder in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a GLP-1 receptor agonist, wherein said administering is performed via inhalation using a soft mist inhaler.

[0178] Embodiment 53. The method of treating or preventing a disorder in a subject in need thereof, according to embodiment 52, wherein the disorder is selected from a metabolic disorder, a cardiovascular disorder, a neurodegenerative disorder, kidney disease, and / or cancer.

[0179] Embodiment 54. The method of treating or preventing a disorder in a subject in need thereof, according to embodiment 53, wherein the disorder is a metabolic disorder.

[0180] Embodiment 55. The method of treating or preventing a disorder in a subject in need thereof, according to embodiment 54, wherein the disorder is obesity and / or type II diabetes.

[0181] Embodiment 56. An inhalable pharmaceutical composition comprising peptide therapeutic, for use in the therapy of a subject; said therapy comprising administering the composition to the subject via a soft mist inhaler.

[0182] Embodiment 57. The inhalable pharmaceutical composition according to embodiment 56, having the features of any of embodiments 2-26 or 40-51.

[0183] Embodiment 58. An aerosolised liquid pharmaceutical composition comprising a peptide therapeutic.

[0184] Embodiment 59. The aerosolised liquid pharmaceutical composition according embodiment 58, having the features of any of embodiments 28-32.

[0185] Embodiment 60. An inhalation device for generating an aerosol, comprising:

[0186] a housing having a user-facing side;

[0187] at least one impingement-type nozzle for generating the aerosol by collision of at least two liquid jets, the nozzle being firmly affixed to the userfacing side of the housing such as to be immobile relative to the housing;a fluid reservoir arranged within the housing; and

[0188] a pumping unit arranged within the housing,

[0189] wherein the fluid reservoir is adapted to hold an inhalable pharmaceutical composition from which the aerosol is generated by the inhalation device; wherein the fluid reservoir comprises an inhalable pharmaceutical composition comprising a peptide therapeutic.

[0190] Embodiment 61. The inhalation device according to embodiment 60, having the features of any of embodiments 38-51.

[0191] Embodiment 62. A kit comprising:

[0192] an inhalation device; and

[0193] an inhalable pharmaceutical composition comprising a peptide therapeutic; wherein the pharmaceutical composition is contained within a cartridge.

[0194] Embodiment 63. The kit according to embodiment 62, having the features of any of embodiments 36-51.

[0195] Embodiment 64. An inhalable pharmaceutical composition comprising or consisting of a GLP-1 receptor agonist, a buffering agent, a salt, a surfactant and a preservative.

[0196] Embodiment 65. The inhalable pharmaceutical composition according to embodiment 64, having the features of any of embodiments 9-11.

[0197] Embodiment 66. A method of treating or preventing a disorder in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a peptide therapeutic, wherein said administering is performed via inhalation using a soft mist inhaler.

[0198] Embodiment 67. The method of embodiment 66, having the features of any of embodiments 53-55.EXAMPLES

[0199] Many modifications and variations of the invention are possible in light of the above teachings. It is therefore understood that, within the scope of the appended claims, a skilled person in the art would recognise that the invention may be practiced otherwise than as specifically described. The illustrative embodiments and examples should not be construed as limiting the invention.

[0200] Example 1 - Droplet Size Distribution

[0201] The capability of the SOFTHALER (hereafter, “soft mist inhaler”) to deliver a formulation of semaglutide was assessed using droplet size distribution using laser diffraction.

[0202] First, semaglutide was harvested from a series of OZEMPIC injector pens (8 mg / 3ml injector pens) by using a syringe and needle to pierce the septum at the front of the pen injector and gently drawing out the solution into the syringe. The solution was then dispensed into a falcon tube. This process was repeated on eight pen injectors in total and all contents were combined within the same falcon tube and stored.

[0203] The harvested OZEMPIC formulation was transferred from the falcon tube to fill soft mist inhaler cartridges. Five cartridges were filled, with a fill volume of 4.3 ml / cartridge. Each cartridge was capped after filling and stored for one week prior to further testing under refrigerated conditions (2-8°C ).

[0204] Droplet size distribution testing by laser light scattering was performed using a MALVERN SPRAYTEC Real Time Spray Droplet Sizing System. The a MALVERN SPRAYTEC generates a He-Ne laser of a maximum 4 mW, with a wavelength of 632.8nm, using a Fourier (parallel beam) lens arrangement. The system used was the short bench laboratory system, fitted with a 950mm optical bench and a 300mm lens focal length. The detector was a 36-element log-spaced array, with automatic alignment. The device was also fitted with a MALVERN SPRAYTEC inhalation cell and a mouthpiece adapter suitable for connecting a soft mist inhaler. The mouthpiece adapter was located 16cm from the laser.

[0205] Prior to the analysis, each soft mist inhaler device was loaded and primed. After inserting each of the five loaded cartridges into a separate soft mist inhaler device each, priming was performed. Each was primed until a visible plume was observed and then subsequently three additional actuations were performed. After priming, the mouthpiece was then wiped with atissue and fitted to the mouthpiece adapter for analysis. The soft mist inhaler was subsequently cleaned after every measured actuation.

[0206] All devices primed well, with four of the five devices producing a plume with the first actuation (n=1), while one device needed two actuations to produce the first plume (n=2).

[0207] The relative humidity was assessed and determined to be above the 50% RH required for DSD testing. The inhalation cell, the gas washing system and additional filters (e.g. vacu-guard) were checked and determined to be clean and well installed. The SPRAYTEC instrument and the five soft mist inhaler products were left to equilibrate in the environmental conditions before testing.

[0208] The system was placed under vacuum, to generate a constant air flow of 28.3 l / min, which was verified at the mouthpiece adaptor and checked until the air flow rate was maintained and stable.

[0209] A soft mist inhaler was then fitted to the mouthpiece adaptor on the inhalation cell and the product was actuated. The soft mist inhaler was fired 60 times. With each actuation, the SPRAYTEC automatically detected the spray and recorded the relevant data. Once the recording was finished, the vacuum was switched off, soft mist inhaler removed, and system cleaned. This process was repeated for each of the five soft mist inhaler devices.

[0210] Each of the five devices was tested and data recorded for each of the actuations (n=60). A summary of the average data recorded across the 5 devices for the event duration, and the percentage volume of droplets with a diameter of less than 5 pm and 10 pm at the Beginning of Life (First 6 actuations, i.e. n=1-6) and the End of Life (Last 6 actuations, i.e. n= 55-60) are provided in Table 1 below:

[0211] TABLE 1

[0212] Beginning of Life Actuation Number

[0213] 1 2 3 4 5 6 Event Duration (s) 1.86 1.86 1.85 1.74 1.75 1.81 Volume < 5 pm (%) 59 59 59 58 59 58 Volume < 10 pm

[0214] 91 91 91 91 90 91 (%)

[0215] End of Life Actuation Number

[0216]

[0217] 55 56 57 58 59 60 Event Duration (s) 1.87 1.84 1.90 1.84 1.85 1.82 Volume < 5 pm (%) 54 56 54 55 55 55 Volume < 10 pm

[0218] 90 91 89 90 90 90 (%)

[0219]

[0220] The droplet size distribution for the devices tested is shown in Figure 7. The average results for the five devices across all the actuations were as shown in Table 2 below:

[0221] TABLE 2

[0222] Parameter Result

[0223] Event duration 1.831 seconds

[0224] Spray weight 12.07 mg

[0225] D10 2.171 pm

[0226] D50 4.529 pm

[0227] D90 9.936 pm

[0228] Span 1.714

[0229]

[0230] D90 represents the droplet size below which 90% of the total volume of droplets is contained. D90 is a common parameter used to characterize droplet size distributions, alongside other values like D10 (below which 10% of the volume is contained) and D50 (the median, or 50% point). D50, or the median droplet diameter, represents the droplet size below which 50% of the total droplet volume is contained, and is a common way to characterize droplet size distributions, providing a single value that summarizes the overall size of droplets. Dm represents the droplet diameter below which 10% of the total droplet volume is found, essentially a percentile of the cumulative volume distribution, and is a measure used in spray and aerosol technology to characterize the smallest droplets within a sample.

[0231] The DSD was determined by calculating the width of the droplet size distribution, which is a dimensionless number also known as “Span.” Span is determined according to the following formula: Span = (D9O-DIO) / D5O, where Dm, D5o, and D90represents the cumulative particle size distribution of 10%, 50%, and 90% particles, respectively, as described above.

[0232] Acceptable dose delivery was observed for all five soft mist inhaler devices that sprayed the harvested OZEMPIC formulation through the inhaler life (60 actuations). When comparing the performance at beginning of life (BoL, first 5 actuations) and the end of life (EoL, last 5actuations), it was observed that there was a minor increase in the ex-nozzle amount at EoL. This is probably due to a minor low performance after priming and was device related. Additionally, the particle size at EoL was slightly more variable than at BoL.

[0233] Example 2 - Dose Purity

[0234] An ultra-performance liquid chromatography (UPLC)-related substances method was used to assess the purity of a semaglutide delivered dose (n = 5) when sprayed by the soft mist inhaler into 4 ml collection vessels.

[0235] Soft mist inhaler-delivered samples were analysed and compared to a control OZEMPIC (semaglutide) 2MG / 0.75ML sample. Consistent results were observed between the soft mist inhaler and control with no evidence of degradation in either samples set.

[0236] Example 3 - Dose Stability Assessment

[0237] The stability of a formulation of a GLP-1 receptor agonist (semaglutide) was assessed in a number of stability studies, which are described in Examples 3a to 3e.

[0238] Example 3a - Visual Semaglutide Stability

[0239] A first stability assessment was conducted by preparing a formulation of semaglutide comprising 45 mg / mL semaglutide in 10mM Tris-HCI, 0.7% w / v NaCI, 0.01% w / v Polysorbate 80 and 0.005% w / v Na-EDTA.

[0240] To monitor the aggregation and stability, several samples were left for up to 3 months, with some samples left at 25°C and others at 2-8°C, whilst protected from light.

[0241] The visual appearance of the solutions on the day of preparation was a clear, colourless solution. The appearance of the solutions on the day of the preparation was compared with the appearance of the solutions after 3 months (approx. 91 days). The comparison identified that, regardless of whether the sample was stored at 25°C or 2-8°C, the solutions remained clear and colourless. No evidence for degradation of the semaglutide in solution was observed.

[0242] Example 3b Semaglutide Stability by RP-HPLC

[0243] The stability of formulated solutions of semaglutide, comprising 45 mg / mL semaglutide in 10mM Tris-HCI, 0.7% w / v NaCI, 0.01% w / v Polysorbate 80 and 0.005% w / v Na-EDTA, was assessed by Reverse Phase High Performance Liquid Chromatography (RP-HPLC).The semaglutide content and impurities of the formulated solutions, before and after actuation by the soft mist inhaler, were assessed by RP-HPLC, both on the day on which it was prepared and was then again after 1 month and 3 months of storage at either 25°C or 2-8°C.

[0244] The average data from duplicate sample preparations pre- and post-actuation through the soft mist inhaler device is summarised in Table 3 below.

[0245] TABLE 3

[0246] % Recovery (vs. theoretical loading) / Total Reportable Impurities (Individual peaks > 0.05%)

[0247] Storage Time

[0248] 0 1 1 3 3 (Months)

[0249] Storage

[0250] - 2-8 25 2-8 25 Temperature (°C)

[0251] Pre-Actuated 102.22 / 102.47 / 101.51 /

[0252] 101.1 / 0.22 98.9 / 1.51 Solution 0.08 0.21 0.51

[0253] Post-Actuated 106.87 / 103.84 / 107.79 /

[0254] 105.2 / 0.30 105.2 / 1.57 Solution 0.00 0.23 0.54

[0255]

[0256] After 3 months storage at 2-8°C and 25°C the assay values remained largely unchanged (vs. T=0 and T=1 month) and the data was also comparable for both pre- and post- soft mist inhaler actuated samples.

[0257] The total reportable impurities continued to increase for the solution held at 25°C (1.51-1.57% area / area at T=3 months), and the total reportable impurities for the solution held at 2-8°C at T=3 months was broadly comparable to T=1 month.

[0258] Accordingly, the RP-HPLC data provided no evidence for degradation of semaglutide in solution, when stored at a reduced temperature (2-8°C).

[0259] Example 3c - Semaglutide Integrity by SE-HPLC

[0260] The stability, in particular the molecular integrity, of formulated solutions of semaglutide, comprising 45 mg / mL semaglutide in 10mM Tris-HCI, 0.7% w / v NaCI, 0.01% w / v Polysorbate80 and 0.005% w / v Na-EDTA, was assessed by Size Exclusion High Performance Liquid Chromatography (SE-HPLC).

[0261] The semaglutide content and impurities of the formulated solutions, before and after actuation by the soft mist inhaler, were assessed by SE-HPLC both on the day on which it was prepared and then again after 1 month and 3 months of storage at either 25°C or 2-8°.

[0262] The average data from duplicate sample preparations pre- and post-actuation through the soft mist inhaler device is summarised in Table 4 below, comparing the relative areas of the peaks directed to a high molecular weight species, likely semaglutide aggregates (HMW-1), the monomer (semaglutide) and the peaks relating to the diluent / EDTA.

[0263] TABLE 4

[0264] Relative Area (%) Storage Storage

[0265] Solution Time Temperature

[0266] Diluent / EDTA (Months) (°C) HMW-1 Monomer Peaks (Excluded)

[0267] 0 - 0.02 99.98 1.81, 2.75, 2.48

[0268] 1 2-8 0.03 99.97 1.85, 2.80, 2.81 Pre-Actuated 1 25 0.08 99.92 1.82, 2.78, 2.61

[0269] 3 2-8 0.07 99.93 0.72,1.80,1.72 3 25 0.20 99.81 0.75,1.68,1.71

[0270] 0 - 0.06 99.94 1.67, 2.78, 2.67

[0271] 1 2-8 0.04 99.96 1.99, 2.71, 2.85 Post- 1 25 0.08 99.92 1.85, 2.77, 2.71 Actuated

[0272] 3 2-8 0.08 99.93 0.73,1.78,1.61 3 25 0.22 99.77 0.80,1.25,1.68

[0273]

[0274] After 3 months of storage at 2-8°C and 25°C the assay values remained largely unchanged

[0275] (vs. T=0 and T=1 month) and the data was also comparable for both pre- and post- soft mist inhaler actuated samples.

[0276] Accordingly, the SE-HPLC data provided no evidence for degradation of semaglutide in solution, and that the integrity of the semaglutide was maintained.

[0277] Example 3d - Semaglutide Stability by NGI

[0278] Changes to the delivered dose, fine particle fraction mass and fine particle fraction (FPF) after actuation through a soft mist inhaler were assessed, following storage of a semaglutide solution.

[0279] A formulated solution of semaglutide, comprising 45 mg / mL semaglutide in 10mM Tris-HCI,

[0280] 0.7% w / v NaCI, 0.01% w / v Polysorbate 80 and 0.005% w / v Na-EDTA, was loaded into a soft mist inhaler assessed by NGI. The semaglutide content and impurities of the formulated solutions were assessed by NGI on the day on which the formulation was prepared, and then reassessed by NGI after the formulation had been stored for 1 or 3 months at either 2-8°C or 25°C. As previously conducted, each device was cleaned after each actuation to ensure optimum actuation conditions.

[0281] The average data from duplicate sample preparations post-actuation through the soft mist inhaler device using an NGI device is summarised in Table 5 below. The data for the emitted fraction, fine particle mass and fine particle fraction are provided for the particle fraction of <5 pm.

[0282] TABLE 5

[0283] Fine Fine

[0284] Median Mass Storage Storage Metered Delivered Emitted Particle Particle Aerodynamic Time Temperature Dose Dose Fraction Mass Fraction

[0285] Diameter (Months) (°C) (mg) (mg) (%) (FPM) (FPF)

[0286] (MMAD) (pm) (mg) (%)

[0287] 0 - 0.63 0.50 79.98 0.12 23.54 6.16

[0288] 1 2-8 0.69 0.53 76.90 0.15 28.23 5.94

[0289]

[0290] 1 25 0.56 0.47 84.69 0.16 34.03 5.81

[0291] 3 2-8 0.56 0.44 78.27 0.13 30.70 6.05

[0292] 3 25 0.64 0.52 81.17 0.13 24.85 6.22

[0293]

[0294] The data shows broadly comparable emitted fractions values for samples after 1 and 3 months of storage. With respect to the dose entering the NGI, %FPF values (<5pm) of 30.70% and 26.50% or0.13 mg and 0.14 mg FPM for solutions stored at2-8°C and 25°C respectively were observed.

[0295] Example 3e - Semaglutide Stability by DSD

[0296] Changes to droplet size distributions after actuation through a soft mist inhaler were assessed, following storage of a semaglutide solution.

[0297] A formulated solution of semaglutide, comprising 45 mg / mL semaglutide in 10mM Tris-HCI, 0.7% w / v NaCI, 0.01% w / v Polysorbate 80 and 0.005% w / v Na-EDTA, was loaded into a soft mist inhaler assessed by DSD using laser diffraction, following storage (1 and 3 months, 2-8°C and 25°C). As previously conducted, each device was cleaned after each actuation to ensure optimum actuation conditions.

[0298] The average data from duplicate sample preparations post-actuation through the soft mist inhaler device using the DSD device is summarised in Table 6 below.

[0299] TABLE 6

[0300] T=0 T=1 M at 2-8°C T=1 M at 25°C T=3M at 2-8°C T=3M at 25°C Std Std Std Std Std Average Average Average Average Average

[0301] Dev Dev Dev Dev Dev Dv10 2.27 0.08 3.69 1.15 2.46 0.171 2.42 0.02 2.40 0.05

[0302] Dv50 4.97 0.30 8.14 1.38 6.71 0.282 5.24 0.16 5.16 0.15

[0303] Dv90 9.81 0.60 14.52 1.51 13.11 0.561 9.68 0.50 9.38 0.34

[0304]

[0305] Volume- Weighted

[0306] 5.56 0.31 8.63 1.31 7.31 0.319 5.67 0.21 5.55 0.14 Mean

[0307] Diameter

[0308] Surface- Weighted

[0309] 3.17 0.27 3.87 1.14 2.65 0.159 3.14 0.49 3.41 0.27 Mean

[0310] Diameter

[0311] Span 1.52 0.01 1.35 0.21 1.59 0.008 1.38 0.05 1.35 0.04 Geometric

[0312] Standard 2.08 - 1.98 - 2.31 - 2.00 - 1.98 - Deviation

[0313] %<5 pm 50.57 4.01 20.11 11.17 31.67 2.305 46.51 2.15 47.66 2.14

[0314]

[0315] The droplet size distributions are shown in Figure 8. After 3 months of storage, the DSD data generated was consistent across each of the two storage conditions (2-8°C and 25°C), and also comparable to that generated at the time the formulations were prepared. Acceptable dose delivery was observed for all soft mist inhaler devices after all storage times.

[0316] Stability Study Conclusion

[0317] The stability of a formulation of a GLP-1 receptor agonist (semaglutide) was assessed in a number of stability studies, which are described above in Examples 3a to 3e. The studies demonstrate that following storage of the formulation (in particular over three months) at lowered temperatures of 2-8°C by refrigeration, there was generally minimal depreciation of the performance of the formulation when delivered by the soft mist inhaler. Furthermore, achieving a high strength formulation of e.g. 45 mg / ml semaglutide is itself surprising and unexpected for inhalation, and may be useful to allow for delivery of therapeutically relevant doses.

Claims

1. CLAIMS1. An inhalable pharmaceutical composition comprising a GLP-1 receptor agonist, for use in the therapy of a subject; said therapy comprising administering the composition to the subject via a soft mist inhaler.

2. The inhalable pharmaceutical composition for use according to claim 1, wherein the GLP- 1 receptor agonist is selected from semaglutide, liraglutide, exenatide, lixisenatide, dulaglutide, albiglutide, beinaglutide, PEG-loxenatide, tirzepatide ASC30 and multiagonist incretin peptides (e.g. dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonists, and triple GLP-1, GIP and glucagon agonists, e.g. retatrutide).

3. The inhalable pharmaceutical composition for use according to claim 2, wherein the GLP- 1 receptor agonist is semaglutide.

4. The inhalable pharmaceutical composition for use according to any one of claims 1 to 3, wherein the therapy is of a disorder in a subject, wherein the disorder is selected from a metabolic disorder, a cardiovascular disorder, a neurodegenerative disorder, kidney disease and cancer.

5. The inhalable pharmaceutical composition for use according to claim 4, wherein the disorder is a metabolic disorder.

6. The inhalable pharmaceutical composition for use according to claim 5, wherein the metabolic disorder is selected from obesity, type II diabetes, hyperglycaemia and impaired glucose tolerance.

7. The inhalable pharmaceutical composition for use according to claim 6, wherein the metabolic disorder is obesity, and wherein the composition is for use in a method of reducing the body weight of the subject, a method of reducing food intake by the subject, or a method of inducing satiety in the subject.

8. The inhalable pharmaceutical composition for use according to any one of claims 1-7, wherein the composition is administered as an aerosol, and wherein the aerosol is produced by at least one impingement-type nozzle for generating the aerosol by collision of at least two liquid jets.

9. The inhalable pharmaceutical composition for use according to any one of claims 1-8, wherein the soft mist inhaler is an inhalation device comprises:a housing having a user-facing side;at least one impingement-type nozzle for generating an aerosol by collision of at least two liquid jets, the nozzle being firmly affixed to the user-facing side of the housing such as to be immobile relative to the housing;a fluid reservoir arranged within the housing; anda pumping unit arranged within the housing,wherein the fluid reservoir is adapted to hold the inhalable pharmaceutical composition from which the aerosol is generated by the inhalation deviceoptionally wherein the fluid reservoir is a cartridge.

10. The inhalable pharmaceutical composition for use according any one of claims 1-9, wherein, following administration, the percentage volume of droplets with a diameter of < 5 pm in the composition is 50% or greater 51% or greater, 52% of greater, 53% or greater, 54% or greater, 55% or greater, 56% or greater, 57% or greater, 58% or greater, or 59% or greater; optionally as measured by droplet size distribution using laser diffraction.

11. The inhalable pharmaceutical composition for use according any one of claims 1-10, wherein, following administration, the percentage volume of droplets with a diameter of < 10 pm in the composition is 89% or greater, 90% or greater, or 91% or greater; optionally as measured by droplet size distribution using laser diffraction.

12. The inhalable pharmaceutical composition for use according to any preceding claim, comprising one or more excipients selected from Tris HCI, NaCI, Polysorbate 80 and Na- EDTA; optionally wherein the composition comprises all of the foregoing excipients; further optionally wherein the pharmaceutical composition consists of the GLP-1 receptor agonist and all of the foregoing excipients.

13. The inhalable pharmaceutical composition for use according to claim 12, wherein the pharmaceutical composition comprises or consists of Tris HCI at from 1 to 20 mM, from 2 to 18 mM, from 3 to 17 mM, from 4 to 16 mM, from 5 to 15 mM, from 6 to 14 mM, from 7 to 13 mM, from 8 to 12 mM, from 9 to 11 mM, about 10 mM or 10mM; NaCI at from 0.1 to 1.0% w / v, from 0.2 to 1.0% w / v, from 0.3 to 1.0% w / v, from 0.4 to 1.0% w / v, from 0.5 to 1.0% w / v, from 0.6 to 0.9% w / v, from 0.6 to 0.8% w / v, about 0.7% w / v, or 0.7% w / v; Polysorbate 80 at from 0.001 to 0.10% w / v, from 0.005 to 0.015% w / v, from 0.006 to 0.014% w / v, from 0.007 to 0.013% w / v, from 0.008 to 0.012% w / v, from 0.009 to 0.011%w / v, about 0.01% w / v, or 0.01% w / v; and EDTA at from 0.001% w / v to 0.01% w / v, from 0.001% to 0.009% w / v, from 0.002% to 0.008% w / v, from 0.003% to 0.007% w / v, from 0.004% to 0.006% w / v, about 0.005% w / v, or 0.005% w / v.

14. The inhalable pharmaceutical composition for use according to claim 13, wherein the pharmaceutical composition comprises the GLP-1 receptor agonist at from 10 to 100 mg / ml, from 20 to 80 mg / ml, from 20 to 70 mg / ml, from 30 to 60 mg / ml, from 40 to 50 mg / ml, from 42 to 48 mg / ml, from 43 to 47 mg / ml, from 44 to 46 mg / ml, about 45 mg / ml or 45 mg / ml; optionally wherein the GLP-1 receptor agonist is semaglutide.

15. An aerosolised liquid pharmaceutical composition comprising a GLP-1 receptor agonist;optionally wherein the GLP-1 receptor agonist is semaglutide.

16. An inhalation device for generating an aerosol, comprising:a housing having a user-facing side;at least one impingement-type nozzle for generating the aerosol by collision of at least two liquid jets, the nozzle being firmly affixed to the user-facing side of the housing such as to be immobile relative to the housing;a fluid reservoir arranged within the housing; anda pumping unit arranged within the housing,wherein the fluid reservoir is adapted to hold an inhalable pharmaceutical composition from which the aerosol is generated by the inhalation device;wherein the fluid reservoir comprises an inhalable pharmaceutical composition comprising a GLP-1 receptor agonist;optionally wherein the GLP-1 receptor agonist is semaglutide;further optionally wherein the fluid reservoir is a cartridge.

17. A kit comprising:an inhalation device; andan inhalable pharmaceutical composition comprising a GLP-1 receptor agonist, wherein the pharmaceutical composition is contained within a cartridge;optionally wherein the GLP-1 receptor agonist is semaglutide.

18. A kit according to claim 17, wherein the inhalation device comprises:a housing having a user-facing side;at least one impingement-type nozzle for generating an aerosol by collision of at least two liquid jets, the nozzle being firmly affixed to the user-facing side of the housing such as to be immobile relative to the housing; anda pumping unit arranged within the housing;andwherein the cartridge is a fluid reservoir, wherein the fluid reservoir is adapted to hold the inhalable pharmaceutical composition from which the aerosol is generated by the inhalation device.

19. The inhalable pharmaceutical composition for use according to any one of claims 1-14, the inhalation device according to claim 16, or the kit according to claim 18, wherein the pumping unit further comprises:a riser pipe having an upstream end, wherein the riser pipe is adapted to function as a piston in the pumping unit, and firmly affixed to the user-facing side of the housing such as to be immobile relative to the housing;a hollow cylinder located upstream of the riser pipe, wherein the upstream end of the riser pipe is inserted in the cylinder such that the cylinder is longitudinally movable on the riser pipe; anda lockable means for storing potential energy when locked and for releasing the stored energy when unlocked, the means being arranged outside of, and mechanically coupled to, the cylinder such that unlocking the means results in a propulsive longitudinal movement of the cylinder towards the downstream end of the pumping unit.

20. The pharmaceutical composition for use, inhalation device or kit according to claim 19, wherein the hollow cylinder is fluidically connected with the fluid reservoir, directly or indirectly.

21. The pharmaceutical composition for use, inhalation device or kit according to claim 19 or 20, wherein the means for storing potential energy is selected from a tension spring, a pressure spring, a magnetic force utilising material or a gaseous medium.

22. The pharmaceutical composition for use, inhalation device or kit according to any of claims 19-21, wherein the pumping unit is a high-pressure pumping unit; and / orthe pumping unit is effective to expel fluid at a pressure of from 2 bar to 1000 bar, 10 bar to 250 bar, or 50 bar to 100 bar.

23. The pharmaceutical composition for use, inhalation device or kit according to any of claims 19-22, wherein the fluid reservoir has a capacity of from 100 pl to 5 mL of the pharmaceutical composition.

24. The pharmaceutical composition for use, inhalation device or kit according to any of claims 19-23, wherein the fluid is drawn in a discrete amount by the pumping unit in a single pumping cycle.

25. The pharmaceutical composition for use, inhalation device or kit according to any of claims 19-24, wherein the volume of fluid that drawn by the pumping unit in a single pumping cycle is from 0.1 to 1000 pl, 1 to 250 pl, or from 2 to 150 pl.

26. The pharmaceutical composition for use, inhalation device or kit according to any of claims 19-25, wherein the device is mechanically or electronically operated.

27. The pharmaceutical composition for use, inhalation device or kit according to any of claims 8-14, 16 or 18 to 26, wherein the at least one impingement-type nozzle(s) are microstructured nozzle(s); optionally wherein the microstructured nozzles comprise a plurality of channels each having a cross section from 1 pm2to 200 pm2, 2 pm2to 200 pm2, 2 pm2to 100 pm2, 5 pm2to 50 pm2, or 10 pm2to 25 pm2.

28. The pharmaceutical composition for use, inhalation device or kit according to any of claims 9-14 or 16 to 267, wherein the decrease in the percentage volume of droplets with a diameter < 5 pm or < 10 pm of the pharmaceutical composition produced over the lifetime of the device is less than 10 %, less than 8%, less than 6%, less than 4%, or less than 2%.

29. The pharmaceutical composition for use, inhalation device or kit according to any of claims 9-14 or 16 to 28, wherein the decrease in the percentage volume of the pharmaceutical composition produced over the lifetime of the device is less than 10 %, less than 8%, less than 6%, less than 4%, or less than 2%.